The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the ...

Ginkgo Bioworks gains a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...